COMMERCIALIZING WORLD-CLASS CANCER INNOVATION

Seeding and scaling Ontario’s premiere entrepreneurial ventures for patients and the economy.

ONTARIO RESEARCH Leveraging breakthrough innovation and community network COMMERCIALIZATION VENTURE Investing seed capital, creating & scaling start-ups, securing strategic partners PATIENT & ECONOMIC IMPACT Driving clinical trials, job creation, talent development, sustainable biotech in Ontario ONTARIO RESEARCH Leveraging breakthrough innovation and community network COMMERCIALIZATION VENTURE Investing seed capital, creating & scaling start-ups, securing strategic partners PATIENT & ECONOMIC IMPACT Driving clinical trials, job creation, talent development, sustainable biotech in Ontario

OUR IMPACT

Increasing the value of Ontario’s best oncology innovations and attracting investment from the private sector.

In total funding and equity investments

In additional financing attracted

Ontario start-ups created

First-in-human studies

PORTFOLIO

Our investments are at the forefront of Ontario’s biotech ecosystem.

FIND OUT MORE

FUNDS

Our investments bridge the life sciences seed funding gap.

FIND OUT MORE

KEY SUCCESSES

Our investments have resulted in significant partnerships, clinical trials, job creation and leveraged financing for the province.

RECENT NEWS

Keep up to date on our investments and business developments in recent news stories and summaries.

  • Women-led health and biotech companies dominate FACIT’s latest investments

    November 20, 2023 – On the globally-recognized Women’s Entrepreneurship Day, FACIT is pleased to announce investments in four breakthrough oncology innovations – all driven by women leaders. November 19th each year is a day to celebrate and showcase women’s contributions to advance communities and to strengthen their empowerment in the entrepreneurial ecosystem to drive economic…

    Read More

  • cTRL Therapeutics announces new Chief Executive Officer to continue advancing its novel immune cell therapy

    November 2, 2023 – cTRL Therapeutics (“cTRL”), a FACIT co-founded and financed company developing novel tumour cell therapies for patients living with cancer, welcomes industry veteran Derrell D. Porter, M.D., as Chief Executive Officer. Read More from cTRL Therapeutics announces new Chief Executive Officer to continue advancing its novel immune cell therapy

    Read More

  • FACIT appoints seasoned life science leaders to its Board of Directors

    November 1, 2023 – FACIT is pleased to welcome two new directors to its Board, Dr. Maura Campbell and Dr. Laszlo Radvanyi. Dedicated to commercializing Ontario intellectual property and impacting patients with cancer, both executives bring with them decades of private and public sector leadership experiences.   Read More from FACIT appoints seasoned life science…

    Read More

  • FACIT and T-CAIREM at the University of Toronto partner to commercialize medical AI

    August 2, 2023 – FACIT and T-CAIREM announce partnership to commercialize medical artificial intelligence (AI) innovations. The partners intend to harness both T-CAIREM’s innovative translational research in AI and FACIT’s unique commercialization-venture model to build the next generation of Ontario biotechnology companies. The joint mission will accelerate the benefits of AI research to support patients…

    Read More

We were established by the Ontario Institute for Cancer Research (OICR) to support commercialization, technology transfer, and development activities. OICR conducts and enables world-class cancer research, filling a critical role as a pan-provincial connector of oncology researchers, resources and cancer innovation development. Together with OICR, we drive a shared vision to attract more R&D investment in Ontario and help the best oncology innovations reach the market and save lives. 

FACIT is funded in part by the Government of Ontario through OICR